Numerous clinical trials spanning Phase 1 through Phase 4 evaluate fulvestrant as a monotherapy and in combination regimens, primarily focusing on hormone receptor-positive breast cancer, metastatic breast cancer, advanced solid tumors, and ovarian cancer. Sponsored by pharmaceutical entities and academic medical centers, these studies encompass completed, actively recruiting, and active but not recruiting cohorts assessing safety, tolerability, and therapeutic efficacy.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07802626 | NOT_YET_RECRUITING | HR Positive/HER-2 Negative Breast Cancer |
SWOG Cancer Research Network |
2026-10-30 | PHASE3 |
| NCT07604571 | RECRUITING | Advanced HR+/HER2- Breast Cancer |
Novartis Pharmaceuticals |
2026-05-28 | PHASE1 |
| NCT07729046 | NOT_YET_RECRUITING | Metastatic Invasive Breast Cancer; Resistant Breast Cancer; ER+, HER2-, Metastatic Breast Cancer |
University of California, San Diego |
2027-07 | PHASE2 |
| NCT07570966 | WITHDRAWN | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Novartis Pharmaceuticals |
2026-06-30 | PHASE1; PHASE2 |
| NCT06849947 | NOT_YET_RECRUITING | Breast Cancer Metastatic |
Yeon Hee Park |
2026-02-01 | PHASE2 |
| NCT07679269 | NOT_YET_RECRUITING | PIK3CA-Related Overgrowth Spectrum (PROS); Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) |
Novartis Pharmaceuticals |
2027-01-01 | PHASE2 |
| NCT07288359 | RECRUITING | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer |
Novartis Pharmaceuticals |
2025-12-29 | PHASE1; PHASE2 |
| NCT07179939 | NOT_YET_RECRUITING | HER2-positive Breast Cancer |
Fudan University |
2025-09-10 | PHASE2 |
| NCT05933395 | RECRUITING | Advanced Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2024-09-23 | PHASE2 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT07716046 | NOT_YET_RECRUITING | Breast Cancer; HER2-positive Breast Cancer; Hormone Receptor-positive Breast Cancer; HR+/HER2+ Breast Cancer |
Fudan University |
2026-10-01 | PHASE2 |
| NCT05564377 | RECRUITING | Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2023-04-07 | PHASE2 |
| NCT05768139 | RECRUITING | Breast Cancer; Solid Tumors, Adult |
Eli Lilly and Company |
2023-04-17 | PHASE1; PHASE2 |
| NCT05161195 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2022-07-07 | PHASE4 |
| NCT07540572 | RECRUITING | ER+, HER 2- Breast Cancer; Non-small Cell Lung Cancer (NSCLC); Castration-resistant Prostate Cancer (CRPC); Microsatellite Stable (MSS) Colorectal Carcinoma |
IDEAYA Biosciences |
2026-03-17 | PHASE1 |
| NCT06380751 | RECRUITING | Advanced Breast Cancer |
AstraZeneca |
2024-08-01 | PHASE3 |
| NCT06120283 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer |
BeOne Medicines |
2023-12-01 | PHASE1 |
| NCT04606446 | RECRUITING | Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Pfizer |
2020-11-16 | PHASE2 |
| NCT07207070 | RECRUITING | Breast Cancer |
Risen (Suzhou) Pharma Tech Co., Ltd. |
2025-11-12 | PHASE3 |
| NCT07558733 | RECRUITING | HR+ HER2- Breast Cancer |
Faeth Therapeutics |
2026-04-22 | PHASE1; PHASE2 |
| NCT07174336 | RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-12-22 | PHASE3 |
| NCT07318805 | RECRUITING | Advanced Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-); Colorectal Cancer; Metastatic Colorectal Adenocarcinoma; Triple Negative Breast Cancer |
Pfizer |
2025-12-23 | PHASE1 |
| NCT05362760 | RECRUITING | Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2022-04-27 | PHASE4 |
| NCT06757634 | RECRUITING | Breast Cancer |
Celcuity Inc |
2025-07-24 | PHASE3 |
| NCT07787520 | NOT_YET_RECRUITING | Patients With Advanced Solid Tumors |
Laekna Limited |
2026-08 | PHASE1 |
| NCT05524584 | RECRUITING | Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer |
University of California, Irvine |
2022-08-31 | PHASE2 |
| NCT05816655 | RECRUITING | Metastatic Breast Cancer |
Korea University Guro Hospital |
2023-05-31 | PHASE2 |
| NCT07109726 | RECRUITING | Breast Cancer; Endometrial Cancer; Ovarian Cancer; Lung Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Solid Tumor; Cervical Cancer |
Terremoto Biosciences Inc. |
2025-09-23 | PHASE1; PHASE2 |
| NCT07405801 | RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2026-04-07 | PHASE2 |
| NCT06997029 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Advanced Ovarian Cancer |
Bristol-Myers Squibb |
2025-08-01 | PHASE1 |
| NCT04646759 | RECRUITING | Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2020-10-14 | PHASE3 |
| NCT07354022 | RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Shandong Suncadia Medicine Co., Ltd. |
2026-05-05 | PHASE3 |
| NCT07389733 | RECRUITING | Advanced Unresectable or Metastatic Breast Cancer of Adults |
Shandong Suncadia Medicine Co., Ltd. |
2026-03-27 | PHASE1; PHASE2 |
| NCT07618390 | NOT_YET_RECRUITING | Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-06 | PHASE2 |
| NCT07784036 | NOT_YET_RECRUITING | Breast Cancer |
Chengdu JOYO pharma Co., Ltd. |
2026-09-30 | PHASE3 |
| NCT07340619 | NOT_YET_RECRUITING | Metastatic (Stage IV) Melanoma |
UNICANCER |
2026-09-18 | PHASE2 |
| NCT07235176 | RECRUITING | Advanced ER+/HER2- Breast Cancer |
Qilu Pharmaceutical Co., Ltd. |
2026-01-16 | PHASE1; PHASE2 |
| NCT07226349 | RECRUITING | Advanced Solid Tumor |
BeOne Medicines |
2025-12-11 | PHASE1 |
| NCT06625775 | RECRUITING | Solid Tumor, Adult; Metastatic Breast Cancer; Advanced Breast Cancer; HER2 Mutation-Related Tumors; HER2-positive Metastatic Breast Cancer; KRAS Mutant Metastatic Colorectal Cancer; Metastatic Lung Cancer; Metastatic Colorectal Cancer; Advanced Lung Cancer; HR-positive, HER2-negative Advanced Breast Cancer; HER2-positive Advanced Breast Cancer |
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) |
2024-10-29 | PHASE1 |
| NCT07368998 | RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2026-02-18 | PHASE2 |
| NCT07767474 | NOT_YET_RECRUITING | Advanced Solid Tumors |
Antares Therapeutics, Inc |
2026-08-01 | PHASE1; PHASE2 |
| NCT07619066 | NOT_YET_RECRUITING | Advanced Breast Cancer; Hormone Receptor Positive / HER2-negative Breast Cancer; HER2 Mutation |
MedSIR |
2026-10-04 | PHASE2 |
| NCT06726148 | RECRUITING | Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Extensive-stage Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2025-04-03 | PHASE1; PHASE2 |
| NCT06680921 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2024-11-14 | PHASE3 |
| NCT07038369 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors; Breast Cancer; Breast Carcinoma; Breast Neoplasms; ER Positive Breast Cancer; Cervical Cancers; Cervical Neoplasms; Cervical Carcinoma; Triple Negative Breast Cancer; Gynecologic Cancers; Gynecologic Neoplasm; Endometrial Cancer; Endometrial Neoplasm; Endometrial Carcinoma (EC); Fallopian Cancer; Ovarian Carcinoma; Ovarian Cancer; Ovarian Neoplasms; Prostate Cancers; Prostate Carcinoma; Solid Tumors; Neoplasms; Neoplasms by Site; Breast Diseases; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms |
Atavistik Bio, Inc |
2025-07-29 | PHASE1 |
| NCT07393321 | NOT_YET_RECRUITING | HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer |
Nanjing Chia-tai Tianqing Pharmaceutical |
2026-02-10 | PHASE3 |
| NCT05467891 | RECRUITING | Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer |
Oana Danciu |
2022-09-13 | PHASE2 |
| NCT06998407 | RECRUITING | HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer |
Avenzo Therapeutics, Inc. |
2025-08-20 | PHASE1; PHASE2 |
| NCT06145308 | RECRUITING | Salivary Gland Carcinoma; Precision Therapy |
Peking Union Medical College |
2023-08-15 | PHASE2 |
| NCT05625087 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage IV |
UNICANCER |
2023-10-19 | PHASE2 |
| NCT07604272 | RECRUITING | Inguinal Hernia Unilateral; Inguinal Hernia Bilateral; Inguinal Hernia Without Obstruction or Gangrene; Inguinal Hernia, Without Mention of Obstruction or Gangrene |
Northwestern University |
2026-07-31 | PHASE1 |
| NCT07666555 | RECRUITING | Breast Cancer |
Fudan University |
2026-06-06 | PHASE2 |
| NCT05154487 | ACTIVE_NOT_RECRUITING | Endometroid Endometrial Cancer |
GOG Foundation |
2024-09-11 | PHASE2 |
| NCT06982521 | RECRUITING | PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer |
Relay Therapeutics, Inc. |
2025-08-26 | PHASE3 |
| NCT06788197 | NOT_YET_RECRUITING | Breast Cancer; Locally Advanced or Metastatic Breast Cancer |
Henan Cancer Hospital |
2025-03 | PHASE1; PHASE2 |
| NCT07480681 | NOT_YET_RECRUITING | Advanced/Metastatic Solid Tumors |
Shanghai Henlius Biotech |
2026-03 | PHASE1 |
| NCT07287917 | RECRUITING | Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer |
Aminex Therapeutics, Inc. |
2026-01-26 | PHASE1; PHASE2 |
| NCT05573126 | RECRUITING | Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer |
Ellipses Pharma |
2023-01-11 | PHASE1; PHASE2 |
| NCT05867251 | RECRUITING | Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer; CCNE1 Amplification; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer |
Avenzo Therapeutics, Inc. |
2023-08-30 | PHASE1; PHASE2 |
| NCT07235618 | NOT_YET_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Sun Yat-sen University |
2026-01-05 | PHASE2 |
| NCT05608252 | RECRUITING | Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer |
Adrienne G. Waks |
2023-02-23 | PHASE1; PHASE2 |
| NCT05601440 | RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2023-06-13 | PHASE2 |
| NCT04567420 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Criterium, Inc. |
2021-02-09 | PHASE2 |
| NCT06764186 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
AstraZeneca |
2025-01-07 | PHASE3 |
| NCT06555068 | RECRUITING | Advanced Unresectable or Metastatic Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2024-08-12 | PHASE1; PHASE2 |
| NCT05683418 | RECRUITING | HR+/HER2-negative Breast Cancer |
Totus Medicines |
2023-02-15 | PHASE1 |
| NCT07333937 | NOT_YET_RECRUITING | Brest Cancer |
Xijing Hospital |
2025-12-20 | PHASE2 |
| NCT06979596 | RECRUITING | Malignant Neoplasm |
Merck Sharp & Dohme LLC |
2025-08-11 | PHASE2 |
| NCT04862663 | ACTIVE_NOT_RECRUITING | Locally Advanced (Inoperable) or Metastatic Breast Cancer |
AstraZeneca |
2021-05-10 | PHASE3 |
| NCT06110793 | RECRUITING | Metastatic Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2023-12-29 | PHASE1; PHASE2 |
| NCT06612814 | ACTIVE_NOT_RECRUITING | Breast Cancer Metastatic |
Zhimin Shao |
2024-09-01 | PHASE3 |
| NCT05090358 | ACTIVE_NOT_RECRUITING | Breast Cancer; Breast Cancer Stage IV; Metastatic Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2021-10-08 | PHASE2 |
| NCT06941142 | NOT_YET_RECRUITING | Advanced Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2025-04-30 | PHASE1 |
| NCT06515470 | RECRUITING | Breast Cancer |
Biotheryx, Inc. |
2024-07-03 | PHASE1 |
| NCT03531645 | ACTIVE_NOT_RECRUITING | Malignant Neoplasms of Female Genital Organs |
M.D. Anderson Cancer Center |
2019-08-13 | PHASE2 |
| NCT04985266 | RECRUITING | ER+ Breast Cancer; HER2-negative Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-03-30 | PHASE2 |
| NCT07180160 | RECRUITING | Advanced Breast Cancer |
Wenjin Yin |
2025-09-25 | PHASE2 |
| NCT05181033 | RECRUITING | Breast Cancer |
National University Hospital, Singapore |
2021-12-27 | PHASE2 |
| NCT06494150 | ACTIVE_NOT_RECRUITING | Low Grade Ovarian Serous Adenocarcinoma |
University of Oklahoma |
2024-12-26 | PHASE2 |
| NCT07029399 | RECRUITING | HR+ Breast Cancer; Triple Negative Breast Cancer (TNBC); CCNE1 Amplified Advanced Solid Tumors; HR+ HER2- Breast Cancer |
NiKang Therapeutics, Inc. |
2025-03-25 | PHASE1 |
| NCT06756932 | RECRUITING | Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer |
BeOne Medicines |
2025-02-04 | PHASE1 |
| NCT05238922 | ACTIVE_NOT_RECRUITING | Solid Tumors |
Incyte Corporation |
2022-07-05 | PHASE1 |
| NCT07062965 | RECRUITING | Breast Cancer |
Pfizer |
2025-08-05 | PHASE3 |
| NCT05735080 | RECRUITING | Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer |
Incyclix Bio |
2023-03-28 | PHASE1; PHASE2 |
| NCT07557004 | ACTIVE_NOT_RECRUITING | HR+ / HER2- Advanced Breast Cancer |
Nanjing Sanhome Pharmaceutical, Co., Ltd. |
2025-09-30 | PHASE1 |
| NCT07498478 | RECRUITING | Breast Cancer |
TransThera Sciences (Nanjing), Inc. |
2026-03-17 | PHASE2 |
| NCT06993844 | RECRUITING | Advanced Solid Tumors; Advanced Breast Cancer |
Ensem Therapeutics |
2025-06-10 | PHASE1; PHASE2 |
| NCT07117630 | RECRUITING | Breast Cancer |
Fudan University |
2025-09-25 | PHASE2 |
| NCT04920708 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-12-28 | PHASE2 |
| NCT06784193 | RECRUITING | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Breast Cancer; Fulvestrant; Palazestrant |
Olema Pharmaceuticals, Inc. |
2024-12-16 | PHASE1 |
| NCT06428396 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Merck Sharp & Dohme LLC |
2024-11-27 | PHASE2 |
| NCT05216432 | RECRUITING | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor |
Relay Therapeutics, Inc. |
2021-12-08 | PHASE1 |
| NCT05472792 | RECRUITING | Breast Cancer; Quality of Life |
UNC Lineberger Comprehensive Cancer Center |
2022-05-17 | PHASE2 |
| NCT07358377 | RECRUITING | Breast Cancer |
Atridia Pty Ltd. |
2026-05-15 | PHASE1 |
| NCT01953588 | ACTIVE_NOT_RECRUITING | Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
Alliance for Clinical Trials in Oncology |
2014-02-27 | PHASE3 |
| NCT05986071 | NOT_YET_RECRUITING | Breast Cancer |
Institut Paoli-Calmettes |
2024-05-01 | PHASE1; PHASE2 |
| NCT05319873 | ACTIVE_NOT_RECRUITING | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Positive Breast Carcinoma; Metastatic HER2-Positive Breast Carcinoma; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
Jonsson Comprehensive Cancer Center |
2022-04-07 | PHASE1; PHASE2 |
| NCT05696626 | RECRUITING | Metastatic Breast Cancer |
LeonaBio |
2023-10-31 | PHASE3 |
| NCT07426822 | RECRUITING | Metastatic HR+/HER2- Breast Cancer |
Maryam Lustberg |
2026-08-15 | PHASE2 |
| NCT06506955 | ACTIVE_NOT_RECRUITING | Advanced/Metastatic Cancer |
Taiho Oncology, Inc. |
2024-10-01 | PHASE2; PHASE3 |
| NCT06736704 | RECRUITING | Advanced Solid Tumors |
Pikavation Therapeutics, Inc. |
2025-02-20 | PHASE1; PHASE2 |
| NCT06409390 | RECRUITING | Metastatic Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2024-08-14 | PHASE2 |
| NCT00585507 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Beth Israel Deaconess Medical Center |
2004-04 | PHASE2 |
| NCT06179303 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma |
University of Washington |
2024-07-22 | PHASE2 |
| NCT04524000 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Novartis Pharmaceuticals |
2021-01-08 | PHASE2 |
| NCT06208410 | RECRUITING | Advanced Solid Tumors |
Risen (Suzhou) Pharma Tech Co., Ltd. |
2024-01-11 | PHASE1; PHASE2 |
| NCT06065748 | RECRUITING | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer |
Hoffmann-La Roche |
2023-12-11 | PHASE3 |
| NCT06447623 | RECRUITING | Advanced Breast Cancer; HR+/HER2- Breast Cancer |
Fudan University |
2024-02-01 | PHASE3 |
| NCT02476786 | RECRUITING | Breast Cancer; Cancer of Breast; Breast Neoplasms; Cancer of the Breast |
Washington University School of Medicine |
2017-01-17 | PHASE2 |
| NCT04544189 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Novartis Pharmaceuticals |
2021-01-20 | PHASE2 |
| NCT05038735 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Novartis Pharmaceuticals |
2021-12-17 | PHASE3 |
| NCT04553133 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer |
Pfizer |
2020-09-16 | PHASE2 |
| NCT06239467 | ACTIVE_NOT_RECRUITING | Advanced Cancer; Breast Cancer; Advanced Solid Tumors; PI3K Gene Mutation |
OnKure, Inc. |
2024-02-26 | PHASE1 |
| NCT05226871 | ACTIVE_NOT_RECRUITING | Breast Cancer; Head and Neck Cancer |
Pfizer |
2022-07-07 | PHASE2 |
| NCT03006172 | ACTIVE_NOT_RECRUITING | Breast Cancer; Solid Tumor |
Genentech, Inc. |
2016-12-13 | PHASE1 |
| NCT05870579 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Novartis Pharmaceuticals |
2023-11-13 | PHASE1 |
| NCT05305924 | RECRUITING | ER-Positive Breast Cancer; HER2-negative Breast Cancer |
The Methodist Hospital Research Institute |
2021-02-25 | PHASE2 |
| NCT04115306 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Phoenix Molecular Designs |
2019-11-14 | PHASE1; PHASE2 |
| NCT07024173 | RECRUITING | Locally Advanced Breast Cancer; Metastatic Breast Cancer |
Shandong Suncadia Medicine Co., Ltd. |
2025-07-23 | PHASE3 |
| NCT05455619 | RECRUITING | HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer |
SynDevRx, Inc. |
2022-08-26 | PHASE1; PHASE2 |
| NCT05307705 | RECRUITING | Breast Cancer |
Eli Lilly and Company |
2022-05-11 | PHASE1 |
| NCT02738866 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2016-10-25 | PHASE2 |
| NCT07163481 | NOT_YET_RECRUITING | Stage IV (Metastatic) Breast Cancer |
Hunan Cancer Hospital |
2025-10 | PHASE1 |
| NCT06202261 | RECRUITING | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-04-13 | PHASE1; PHASE2 |
| NCT05646862 | RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2023-06-07 | PHASE3 |
| NCT06663072 | RECRUITING | Metastatic Pancreatic Neuroendocrine Tumor |
University of Chicago |
2024-12-13 | PHASE1 |
| NCT06016738 | ACTIVE_NOT_RECRUITING | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma |
Olema Pharmaceuticals, Inc. |
2023-11-16 | PHASE3 |
| NCT06635447 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2024-09-26 | PHASE3 |
| NCT04851613 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Laekna Limited |
2022-02-18 | PHASE3 |
| NCT06929325 | NOT_YET_RECRUITING | HR+/HER2- Advanced/Metastatic Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2025-04 | PHASE3 |
| NCT04557449 | ACTIVE_NOT_RECRUITING | Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung |
Pfizer |
2020-09-23 | PHASE2 |
| NCT05113368 | RECRUITING | Ovarian Cancer; Serous Ovarian Cancer |
Sarah K. Lynam MD |
2022-06-28 | PHASE2 |
| NCT06257264 | ACTIVE_NOT_RECRUITING | Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer |
BeiGene |
2024-03-11 | PHASE1 |
| NCT05262400 | ACTIVE_NOT_RECRUITING | Breast Cancer; Solid Tumors |
Pfizer |
2022-03-14 | PHASE1; PHASE2 |
| NCT05251714 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor; Breast Cancer |
Treadwell Therapeutics, Inc |
2022-05-27 | PHASE1; PHASE2 |
| NCT07408089 | TERMINATED | Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer |
Boundless Bio, Inc. |
2026-02-25 | PHASE1 |
| NCT05949541 | RECRUITING | Breast Cancer; Advanced Breast Cancer |
Fudan University |
2023-07-26 | PHASE2 |
| NCT05501886 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Celcuity Inc |
2022-12-08 | PHASE3 |
| NCT06607757 | RECRUITING | CCCA Assessed by Ki67 Drop Below <2.7% From Baseline |
GBG Forschungs GmbH |
2024-12-04 | PHASE2 |
| NCT04572295 | COMPLETED | Breast Neoplasms |
Eisai Co., Ltd. |
2020-10-09 | PHASE1 |
| NCT06702618 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2025-02-20 | PHASE2 |
| NCT05063786 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Spanish Breast Cancer Research Group |
2021-09-14 | PHASE3 |
| NCT06339281 | NOT_YET_RECRUITING | Advanced Breast Cancer |
Li Huiping |
2024-05-01 | PHASE2 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT07366632 | NOT_YET_RECRUITING | Postmenopausal Women |
Shanghai Best-Link Bioscience, LLC |
2026-01-26 | PHASE1 |
| NCT05392608 | ACTIVE_NOT_RECRUITING | Neoplasm, Breast; Congenital, Familial and Genetic Disorders |
Borstkanker Onderzoek Groep |
2022-06-02 | PHASE2 |
| NCT06995482 | RECRUITING | Healthy Postmenopausal Women |
Kashiv BioSciences, LLC |
2025-08-18 | PHASE1 |
| NCT04872166 | RECRUITING | Advanced Solid Tumor; Metastatic Breast Cancer |
Edgewood Oncology Inc. |
2021-06-07 | PHASE1 |
| NCT06253195 | COMPLETED | Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer |
BeOne Medicines |
2024-04-01 | PHASE1 |
| NCT05905341 | WITHDRAWN | Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors |
Pfizer |
2024-01-15 | PHASE1 |
| NCT05230810 | ACTIVE_NOT_RECRUITING | HER2-positive Metastatic Breast Cancer |
Criterium, Inc. |
2022-08-25 | PHASE1; PHASE2 |
| NCT05207709 | TERMINATED | Metastatic Breast Cancer |
SOLTI Breast Cancer Research Group |
2022-03-28 | PHASE3 |
| NCT03643510 | COMPLETED | Adenocarcinoma of Endometrium |
Memorial Sloan Kettering Cancer Center |
2018-08-21 | PHASE2 |
| NCT06998108 | RECRUITING | HR+/HER2- Locally Advanced, Metastatic Breast Cancer |
BeBetter Med Inc |
2022-06-09 | PHASE3 |
| NCT06561022 | UNKNOWN | Breast Cancer |
Fudan University |
2024-08-21 | PHASE2 |
| NCT06750848 | NOT_YET_RECRUITING | Advanced Breast Cancer |
Jundong Wu |
2024-12-20 | PHASE2 |
| NCT05536128 | RECRUITING | Advanced Breast Cancer |
Seoul National University Hospital |
2022-12-31 | PHASE2 |
| NCT06408168 | TERMINATED | Hormone Receptor-positive Human Epidermal Growth Factor 2-negative; Metastatic Invasive LObular Carcinoma |
M.D. Anderson Cancer Center |
2024-08-08 | PHASE2 |
| NCT05594095 | RECRUITING | Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor; HER2-negative Breast Cancer; Advanced Breast Cancer |
Fudan University |
2022-12-30 | PHASE2 |
| NCT06851442 | TERMINATED | Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2025-05-16 | PHASE1; PHASE2 |
| NCT05759546 | RECRUITING | Breast Cancer Metastatic |
Fudan University |
2023-02-01 | PHASE2 |
| NCT05759572 | RECRUITING | Breast Cancer Metastatic |
Fudan University |
2023-02-01 | PHASE2 |
| NCT02778685 | ACTIVE_NOT_RECRUITING | Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 |
City of Hope Medical Center |
2016-09-30 | PHASE2 |
| NCT04762979 | ACTIVE_NOT_RECRUITING | Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer; PIK3CA Mutant Metastatic Breast Cancer |
Marina N Sharifi |
2021-02-12 | PHASE2 |
| NCT06856200 | RECRUITING | Advanced HR - Positive, HER2 - Negative Breast Cancer; Resistant to (Neo)Adjuvant Endocrine Therapy |
Fudan University |
2025-02-28 | |
| NCT02760030 | COMPLETED | Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
Ohio State University Comprehensive Cancer Center |
2017-02-16 | PHASE2 |
| NCT03685331 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation |
Abramson Cancer Center at Penn Medicine |
2020-10-15 | PHASE1 |
| NCT05306340 | ACTIVE_NOT_RECRUITING | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer |
Genentech, Inc. |
2022-08-03 | PHASE3 |
| NCT05252416 | TERMINATED | Advanced Solid Tumors; HR+ Breast Cancer; CCNE1 Amplification; HER2-negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Gastric Cancer; Esophageal Adenocarcinoma; Carcinosarcoma |
Blueprint Medicines Corporation |
2022-04-07 | PHASE1 |
| NCT05365178 | ACTIVE_NOT_RECRUITING | HR-positive, HER2-negative Breast Neoplasms |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-07-01 | PHASE3 |
| NCT04498520 | WITHDRAWN | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8 |
Pamela Munster |
2021-03-31 | PHASE1 |
| NCT04352777 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor |
Duke University |
2020-09-14 | PHASE2 |
| NCT02792465 | COMPLETED | Advanced Solid Cancers; Breast Cancer |
University Health Network, Toronto |
2016-11-11 | PHASE1 |
| NCT05631795 | COMPLETED | Advanced Breast Cancer |
Novartis Pharmaceuticals |
2022-08-09 | PHASE4 |
| NCT05191004 | WITHDRAWN | Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast Tumor |
Nuvation Bio Inc. |
2022-09 | PHASE1; PHASE2 |
| NCT06957379 | ACTIVE_NOT_RECRUITING | HR+/HER2- Advanced/Metastatic Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2024-02-29 | PHASE2 |
| NCT04650581 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2021-01-27 | PHASE3 |
| NCT03781063 | COMPLETED | Locally Advanced or Metastatic Breast Cancer |
Sermonix Pharmaceuticals Inc. |
2019-09-20 | PHASE2 |
| NCT04263298 | RECRUITING | Metastatic Breast Cancer |
Herui Yao |
2018-05-01 | PHASE3 |
| NCT04158362 | ACTIVE_NOT_RECRUITING | Cancer Metastatic |
UNICANCER |
2020-06-11 | PHASE3 |
| NCT05554354 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma |
National Cancer Institute (NCI) |
2024-09-13 | PHASE2 |
| NCT06172322 | UNKNOWN | HR Positive/HER-2 Negative Breast Cancer |
Nanjing Chia-tai Tianqing Pharmaceutical |
2023-12-28 | PHASE1 |
| NCT05963984 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer |
Carrick Therapeutics Limited |
2023-11-16 | PHASE2 |
| NCT05759949 | COMPLETED | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor |
Relay Therapeutics, Inc. |
2023-03-29 | PHASE1 |
| NCT05463601 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-08-01 | PHASE2 |
| NCT02344472 | UNKNOWN | Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2015-09 | PHASE3 |
| NCT05654623 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Pfizer |
2023-03-03 | PHASE3 |
| NCT02958852 | COMPLETED | Breast Cancer |
Lund University Hospital |
2025-01-02 | PHASE2 |
| NCT05574881 | UNKNOWN | Breast Cancer |
Fudan University |
2022-09-01 | PHASE1; PHASE2 |
| NCT05806671 | UNKNOWN | Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05 | PHASE2 |
| NCT04092673 | UNKNOWN | Solid Tumor, Adult |
Effector Therapeutics |
2019-10-25 | PHASE1; PHASE2 |
| NCT05720260 | RECRUITING | Premenopausal Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer |
National Taiwan University Hospital |
2023-01-17 | PHASE2 |
| NCT04282031 | UNKNOWN | Advanced Solid Tumor; HR+/HER2- Breast Cancer |
Beta Pharma (Suzhou) Co., Ltd. |
2020-06-15 | PHASE1; PHASE2 |
| NCT02947685 | ACTIVE_NOT_RECRUITING | HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer |
Alliance Foundation Trials, LLC. |
2017-06-21 | PHASE3 |
| NCT03280563 | COMPLETED | Breast Neoplasms |
Hoffmann-La Roche |
2017-12-22 | PHASE1; PHASE2 |
| NCT05577923 | UNKNOWN | Metastatic Breast Cancer |
Fudan University |
2022-11-01 | PHASE2 |
| NCT03620643 | COMPLETED | Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation |
Royal Marsden NHS Foundation Trust |
2019-05-09 | PHASE2 |
| NCT03355157 | COMPLETED | Metastatic Breast Cancer |
GBG Forschungs GmbH |
2018-03-01 | PHASE4 |
| NCT05966584 | TERMINATED | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2023-07-06 | PHASE2 |
| NCT04227327 | TERMINATED | Advanced Breast Cancer |
University of Milano Bicocca |
2020-01-07 | PHASE2 |
| NCT02206984 | COMPLETED | Breast Cancer |
Priscilla McAuliffe |
2015-09-30 | PHASE2 |
| NCT05176080 | TERMINATED | Metastatic Breast Cancer |
Henan Cancer Hospital |
2021-12-08 | PHASE1; PHASE2 |
| NCT04901299 | WITHDRAWN | Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast Cancer |
Massachusetts General Hospital |
2023-07 | PHASE2 |
| NCT04603183 | COMPLETED | Breast Cancer Metastatic |
MedSIR |
2021-06-02 | PHASE2 |
| NCT04975308 | ACTIVE_NOT_RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-10-04 | PHASE3 |
| NCT05101564 | COMPLETED | Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer |
Jennifer Lee Caswell-Jin |
2023-03-20 | PHASE2 |
| NCT05328440 | UNKNOWN | Breast Neoplasms |
Henan Cancer Hospital |
2022-05-20 | PHASE2 |
| NCT04796623 | COMPLETED | HR-positive, HER2-negative Advanced Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2021-02-04 | PHASE2 |
| NCT05082025 | TERMINATED | Endometrial Cancer; Ovarian Cancer |
M.D. Anderson Cancer Center |
2022-09-27 | PHASE2 |
| NCT04726332 | TERMINATED | Neoplasm Malignant; Epithelial Ovarian Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Exelixis |
2021-02-10 | PHASE1 |
| NCT05806047 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
Fudan University |
2023-05-01 | PHASE2 |
| NCT04337658 | UNKNOWN | HER2-positive Breast Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-07-01 | PHASE3 |
| NCT05384119 | TERMINATED | Breast Cancer |
Tvardi Therapeutics, Incorporated |
2023-01-09 | PHASE1 |
| NCT05079360 | WITHDRAWN | Metastatic Breast Cancer |
Veru Inc. |
2023-03-15 | PHASE2 |
| NCT06239467 | Recruiting | Advanced Cancer|Breast Cancer |
OnKure Inc. |
2024-03-01 | Phase 1 |
| NCT03767335 | COMPLETED | Advanced or Metastatic Breast Cancer |
Menarini Group |
2018-11-13 | PHASE1 |
| NCT05077449 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Xuanzhu Biopharmaceutical Co., Ltd. |
2021-11-16 | PHASE3 |
| NCT05438810 | UNKNOWN | Advanced Breast Cancer; Female Breast Cancer |
Ahon Pharmaceutical Co., Ltd. |
2022-01-18 | PHASE3 |
| NCT05169567 | ACTIVE_NOT_RECRUITING | Breast Neoplasm; Neoplasm Metastasis |
Eli Lilly and Company |
2022-03-11 | PHASE3 |
| NCT06257264 | Recruiting | Breast Cancer|Small Cell Lung Cancer|Ovarian Cancer|Gastric Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Advanced Solid Tumor|Endometrial Cancer|Prostate Cancer |
BeiGene |
2024-02-28 | Phase 1 |
| NCT06047184 | COMPLETED | Advanced Breast Cancer |
BeBetter Med Inc |
2019-07-15 | PHASE1 |
| NCT05375461 | COMPLETED | HR-positive,HER2-negative in Advanced Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-03-18 | PHASE3 |
| NCT05905341 | Withdrawn | Breast Cancer|Ovarian Cancer|Liposarcoma|Non-small Cell Lung Cancer (NSCLC)|Endometrial|Solid Tumors |
Pfizer |
2024-01-15 | Phase 1 |
| NCT05186545 | UNKNOWN | Breast Cancer; Breast Cancer Female |
The First Affiliated Hospital of Zhengzhou University |
2022-07-01 | PHASE2 |
| NCT03554044 | COMPLETED | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma |
University of California, San Francisco |
2020-02-05 | PHASE1 |
| NCT05433480 | UNKNOWN | Breast Cancer |
Betta Pharmaceuticals Co., Ltd. |
2022-05-25 | PHASE3 |
| NCT04334330 | UNKNOWN | Breast Cancer; Brain Metastases |
Sun Yat-sen University |
2020-12-04 | PHASE2 |
| NCT03439046 | TERMINATED | Breast Cancer |
Novartis Pharmaceuticals |
2018-02-02 | PHASE3 |
| NCT04999540 | UNKNOWN | Breast Cancer |
Guangdong Women and Children Hospital |
2021-11-01 | PHASE2 |
| NCT05963984 | Recruiting | Metastatic Breast Cancer|Locally Advanced Breast Cancer|Breast Cancer |
Carrick Therapeutics Limited|Pfizer |
2023-12-14 | Phase 2 |
| NCT05085002 | TERMINATED | Advanced Breast Cancer |
EQRx, Inc. |
2021-12-21 | PHASE2 |
| NCT04053322 | ACTIVE_NOT_RECRUITING | ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status |
UNICANCER |
2019-08-26 | PHASE2 |
| NCT04579380 | ACTIVE_NOT_RECRUITING | Uterine Neoplasms; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Urologic Neoplasms; Carcinoma, Non-Small-Cell Lung; HER2 Mutations Breast Neoplasms |
Seagen, a wholly owned subsidiary of Pfizer |
2021-01-11 | PHASE2 |
| NCT03854903 | COMPLETED | Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer |
Georgetown University |
2019-04-01 | PHASE1 |
| NCT05065411 | TERMINATED | Metastatic Breast Cancer |
Veru Inc. |
2022-04-11 | PHASE3 |
| NCT05076695 | UNKNOWN | Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer |
Fudan University |
2021-10-15 | PHASE2 |
| NCT04191499 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2020-01-29 | PHASE2; PHASE3 |
| NCT04256941 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-05-31 | PHASE2 |
| NCT06074757 | COMPLETED | Metastatic Breast Cancer |
Kashiv BioSciences, LLC |
2023-03-01 | PHASE1 |
| NCT05808582 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2023-05-01 | PHASE2 |
| NCT05075512 | UNKNOWN | Breast Neoplasm Female |
Zhejiang Cancer Hospital |
2021-09-01 | PHASE2 |
| NCT04060862 | TERMINATED | Breast Cancer |
Hoffmann-La Roche |
2019-11-21 | PHASE1 |
| NCT04556773 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
AstraZeneca |
2020-12-17 | PHASE1 |
| NCT03393845 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Nancy Chan, MD |
2018-01-29 | PHASE2 |
| NCT04539496 | ACTIVE_NOT_RECRUITING | Metastasis Solid Tumors; Advanced Breast Cancer |
Sihuan Pharmaceutical Holdings Group Ltd. |
2018-05-22 | PHASE1; PHASE2 |
| NCT04318223 | UNKNOWN | Metastatic Breast Cancer; Locally Advanced Breast Cancer |
Consorzio Oncotech |
2019-07-16 | PHASE2 |
| NCT05504213 | UNKNOWN | Breast Cancer |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2022-01-12 | PHASE1 |
| NCT03939897 | ACTIVE_NOT_RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Recurrent Breast Carcinoma |
National Cancer Institute (NCI) |
2020-06-17 | PHASE1 |
| NCT03772353 | UNKNOWN | Breast Cancer |
Fudan University |
2019-05-12 | PHASE1; PHASE2 |
| NCT04936295 | UNKNOWN | Breast Cancer |
Sun Yat-sen University |
2021-06-16 | PHASE2 |
| NCT02983071 | UNKNOWN | Carcinoma, Ductal, Breast; Breast Cancer; Breast Neoplasm |
G1 Therapeutics, Inc. |
2017-01 | PHASE1; PHASE2 |
| NCT04024436 | TERMINATED | Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification |
Taiho Oncology, Inc. |
2020-01-28 | PHASE2 |
| NCT03099174 | COMPLETED | Neoplasms; Breast Neoplasms |
Boehringer Ingelheim |
2017-05-04 | PHASE1 |
| NCT04899349 | TERMINATED | Breast Cancer |
Novartis Pharmaceuticals |
2022-04-06 | PHASE2 |
| NCT04305496 | ACTIVE_NOT_RECRUITING | Locally Advanced (Inoperable) or Metastatic Breast Cancer |
AstraZeneca |
2020-04-16 | PHASE3 |
| NCT03310541 | COMPLETED | Breast Cancer; Prostate Cancer; Advanced Solid Tumors |
Memorial Sloan Kettering Cancer Center |
2017-10-11 | PHASE1 |
| NCT06129786 | Recruiting | Breast Cancer |
Centro di Riferimento Oncologico - Aviano |
2023-05-18 | -- |
| NCT04224272 | COMPLETED | HER2+/HR+ Breast Cancer |
Jazz Pharmaceuticals |
2020-06-10 | PHASE2 |
| NCT04483505 | COMPLETED | Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast |
Fundacion CRIS de Investigación para Vencer el Cáncer |
2020-11-25 | PHASE1 |
| NCT04738292 | TERMINATED | ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer |
University of Wisconsin, Madison |
2021-10-05 | PHASE2 |
| NCT03425838 | ACTIVE_NOT_RECRUITING | Breast Neoplasm Female |
Borstkanker Onderzoek Groep |
2017-11-09 | PHASE3 |
| NCT02955394 | ACTIVE_NOT_RECRUITING | Breast Cancer |
University of Colorado, Denver |
2017-09-21 | PHASE2 |
| NCT02894398 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
iOMEDICO AG |
2016-09-06 | PHASE2 |
| NCT04247126 | COMPLETED | Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer |
Syros Pharmaceuticals |
2020-01-23 | PHASE1 |
| NCT04753177 | UNKNOWN | The Neoadjuvant Therapy |
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary |
2021-01-28 | PHASE2; PHASE3 |
| NCT04707196 | COMPLETED | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-02-22 | PHASE4 |
| NCT03147287 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Dana-Farber Cancer Institute |
2017-09-05 | PHASE2 |
| NCT03959891 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Massachusetts General Hospital |
2019-05-30 | PHASE1 |
| NCT03363893 | COMPLETED | Advanced Solid Malignancies |
Carrick Therapeutics Limited |
2017-11-14 | PHASE1; PHASE2 |
| NCT05054751 | COMPLETED | Locally Advanced or Metastatic Breast Cancer |
Genor Biopharma Co., Ltd. |
2021-09-10 | PHASE3 |
| NCT05025735 | UNKNOWN | Metastatic Breast Cancer; HER2-negative Breast Cancer |
Saint Luke's Health System |
2021-08-25 | PHASE2 |
| NCT00253422 | COMPLETED | Breast Cancer |
Institute of Cancer Research, United Kingdom |
2004-03-26 | PHASE3 |
| NCT03386162 | TERMINATED | Breast Cancer, PI3K, Alpelisib |
UNICANCER |
2018-03-15 | PHASE2 |
| NCT03182634 | UNKNOWN | Advanced Breast Cancer |
Institute of Cancer Research, United Kingdom |
2016-12-15 | PHASE2 |
| NCT03691493 | COMPLETED | Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8 |
Emory University |
2019-02-08 | PHASE2 |
| NCT02333370 | COMPLETED | Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer |
Novartis Pharmaceuticals |
2015-02-04 | PHASE1 |
| NCT04862143 | TERMINATED | Advanced Breast Cancer |
Novartis Pharmaceuticals |
2022-03-08 | PHASE2 |
| NCT04214288 | ACTIVE_NOT_RECRUITING | Advanced ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2020-04-22 | PHASE2 |
| NCT05191914 | UNKNOWN | Breast Cancer |
Liaoning Cancer Hospital & Institute |
2022-02-07 | PHASE4 |
| NCT03481998 | COMPLETED | Advanced Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2018-03-22 | PHASE1; PHASE2 |
| NCT03555877 | COMPLETED | Breast Cancer Metastatic |
GBG Forschungs GmbH |
2018-03-15 | PHASE2 |
| NCT03308201 | COMPLETED | Breast Cancer |
Tianjin Hemay Pharmaceutical Co., Ltd |
2017-10-16 | PHASE1 |
| NCT05047848 | UNKNOWN | Advanced Breast Cancer |
Liaoning Cancer Hospital & Institute |
2021-08-18 | |
| NCT03560856 | UNKNOWN | Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis |
Assistance Publique - Hôpitaux de Paris |
2018-06-27 | PHASE2 |
| NCT00738777 | SUSPENDED | Breast Cancer |
The Netherlands Cancer Institute |
2008-07 | PHASE2 |
| NCT02913430 | COMPLETED | Metastatic Breast Cancer |
Shannon Puhalla |
2018-04-24 | EARLY_PHASE1 |
| NCT03926936 | COMPLETED | Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor |
Frederic Amant |
2019-03-13 | PHASE2 |
| NCT04856371 | UNKNOWN | Advanced Breast Cancer |
Haihe Biopharma Co., Ltd. |
2021-04 | PHASE1 |
| NCT03803761 | WITHDRAWN | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-02-13 | PHASE1; PHASE2 |
| NCT04576455 | ACTIVE_NOT_RECRUITING | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer |
Hoffmann-La Roche |
2020-11-27 | PHASE2 |
| NCT04305236 | TERMINATED | Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma |
University of California, Irvine |
2020-07-23 | PHASE2 |
| NCT04059484 | TERMINATED | Breast Cancer Metastatic |
Sanofi |
2019-10-22 | PHASE2 |
| NCT02684032 | COMPLETED | Breast Cancer |
Celcuity Inc |
2016-06-14 | PHASE1 |
| NCT02860000 | COMPLETED | Estrogen Receptor Status; HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
Mayo Clinic |
2017-07-06 | PHASE2 |
| NCT02632045 | COMPLETED | Metastatic Breast Cancer; Breast Carcinoma |
Melissa K Accordino |
2016-03 | PHASE2 |
| NCT02216786 | COMPLETED | Estrogen Receptor Positive Breast Cancer |
Queen Mary University of London |
2014-01-16 | PHASE2 |
| NCT05004142 | UNKNOWN | Breast Neoplasms |
Ahon Pharmaceutical Co., Ltd. |
2020-06-30 | PHASE2 |
| NCT03927456 | UNKNOWN | Advanced Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2019-06-13 | PHASE3 |
| NCT03220178 | TERMINATED | Breast Neoplasm |
Palleos Healthcare GmbH |
2017-07-24 | PHASE4 |
| NCT03462251 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; HER 2 Negative Breast Cancer |
iOMEDICO AG |
2018-05-24 | PHASE3 |
| NCT03344536 | COMPLETED | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2017-11-10 | PHASE1; PHASE2 |
| NCT03591549 | UNKNOWN | Metastatic Breast Cancer |
Assiut University |
2018-08-01 | PHASE4 |
| NCT03289039 | TERMINATED | Breast Cancer |
Dana-Farber Cancer Institute |
2017-10-25 | PHASE2 |
| NCT04034589 | UNKNOWN | Metastatic Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2019-07-17 | PHASE2 |
| NCT02340221 | TERMINATED | Breast Cancer |
Hoffmann-La Roche |
2015-04-09 | PHASE3 |
| NCT01296555 | TERMINATED | Solid Cancers; Non-Hodgkin's Lymphoma |
Genentech, Inc. |
2011-03-16 | PHASE1 |
| NCT03056755 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2017-08-29 | PHASE2 |
| NCT04355520 | UNKNOWN | HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-07 | PHASE1; PHASE2 |
| NCT03322215 | TERMINATED | Breast Cancer Metastatic |
Theodoros Foukakis |
2017-10-24 | PHASE2 |
| NCT03238196 | COMPLETED | Metastatic Breast Cancer |
Vanderbilt-Ingram Cancer Center |
2017-08-18 | PHASE1 |
| NCT03447132 | COMPLETED | Breast Neoplasm Female |
International Cancer Research Group, United Arab Emirates |
2017-12-20 | PHASE3 |
| NCT02057133 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-03-10 | PHASE1 |
| NCT02761694 | TERMINATED | Cancer; Solid Tumors |
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
2016-06-26 | PHASE1 |
| NCT04033172 | UNKNOWN | Breast Cancer; HER2-positive Breast Cancer |
Chinese Academy of Medical Sciences |
2018-11-01 | PHASE2 |
| NCT01670877 | COMPLETED | Breast Neoplasms |
Washington University School of Medicine |
2012-12-11 | PHASE2 |
| NCT02384239 | COMPLETED | Metastatic Breast Cancer; Hormone Receptor Positive |
University of California, San Francisco |
2015-10-19 | PHASE2 |
| NCT02269670 | TERMINATED | Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
Emory University |
2014-11-25 | PHASE2 |
| NCT03294694 | TERMINATED | Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer |
Dana-Farber Cancer Institute |
2017-11-08 | PHASE1 |
| NCT02964507 | TERMINATED | Neoplasms |
GlaxoSmithKline |
2019-09-26 | PHASE1 |
| NCT02536742 | COMPLETED | Metastatic Breast Cancer |
ETOP IBCSG Partners Foundation |
2016-08-30 | PHASE2 |
| NCT02657343 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2016-03-09 | PHASE1; PHASE2 |
| NCT02540330 | TERMINATED | Female Breast Carcinoma; Female Ductal Carcinoma In Situ |
Atossa Therapeutics, Inc. |
2016-03 | PHASE2 |
| NCT04031885 | TERMINATED | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-08-14 | PHASE4 |
| NCT03584009 | TERMINATED | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-09-06 | PHASE2 |
| NCT03134638 | TERMINATED | Advanced Solid Tumors; Ovarian Cancer; Breast Cancer |
Syros Pharmaceuticals |
2017-05-12 | PHASE1 |
| NCT02936206 | TERMINATED | Breast Cancer |
Icahn School of Medicine at Mount Sinai |
2016-10 | PHASE1 |
| NCT03007979 | COMPLETED | Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast |
Washington University School of Medicine |
2017-06-15 | PHASE2 |
| NCT03024580 | UNKNOWN | Breast Neoplasm |
Instituto Nacional de Cancer, Brazil |
2017-03-06 | PHASE2 |
| NCT02569801 | TERMINATED | Breast Cancer |
Genentech, Inc. |
2015-12-04 | PHASE2 |
| NCT02690480 | UNKNOWN | Breast Neoplasms |
Spanish Breast Cancer Research Group |
2016-02-17 | PHASE2 |
| NCT02491983 | COMPLETED | Metastatic Breast Cancer |
MedSIR |
2015-08 | PHASE2 |
| NCT02137837 | TERMINATED | Breast Cancer |
SWOG Cancer Research Network |
2014-05 | PHASE3 |
| NCT02692755 | COMPLETED | Hormone Receptor Positive HER-2 Negative Breast Cancer |
Georgetown University |
2016-09 | PHASE2; PHASE3 |
| NCT02646735 | UNKNOWN | Breast Cancer |
Chinese Academy of Medical Sciences |
2015-12 | PHASE2 |
| NCT02756364 | COMPLETED | Breast Neoplasms |
Calithera Biosciences, Inc |
2016-07-28 | PHASE2 |
| NCT02953860 | COMPLETED | Breast Cancer |
University of Colorado, Denver |
2017-07-06 | PHASE2 |
| NCT03202862 | UNKNOWN | Breast Neoplasms |
Fudan University |
2017-07-01 | PHASE2 |
| NCT02675231 | COMPLETED | Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer |
Eli Lilly and Company |
2016-05-23 | PHASE2 |
| NCT01655225 | COMPLETED | Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer |
Eli Lilly and Company |
2012-07-31 | PHASE1 |
| NCT02763566 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2016-12-05 | PHASE3 |
| NCT01992952 | ACTIVE_NOT_RECRUITING | Estrogen Receptor Positive Breast Cancer |
Velindre NHS Trust |
2014-05-07 | PHASE1; PHASE2 |
| NCT03236974 | COMPLETED | Postmenopausal Women With ER+ HER2- Primary Breast Cancer |
AstraZeneca |
2017-10-05 | PHASE1 |
| NCT03197584 | WITHDRAWN | Ovarian Cancer |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT02291913 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2014-12-18 | PHASE2 |
| NCT03192293 | UNKNOWN | Breast Cancer |
National University Hospital, Singapore |
2017-01-20 | PHASE2 |
| NCT02028507 | COMPLETED | Metastatic Breast Cancer |
Spanish Breast Cancer Research Group |
2014-03-13 | PHASE3 |
| NCT03169777 | WITHDRAWN | Colorectal Cancer |
ImmunityBio, Inc. |
2018-08 | PHASE1; PHASE2 |
| NCT03169738 | WITHDRAWN | Non-small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-02 | PHASE1; PHASE2 |
| NCT02970682 | COMPLETED | Breast Neoplasm |
Evgen Pharma |
2016-10 | PHASE2 |
| NCT03169764 | WITHDRAWN | Head and Neck Squamous Cell Carcinoma |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT03197571 | WITHDRAWN | Urothelial Carcinoma |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT02911844 | COMPLETED | Pulmonary Arterial Hypertension |
University of Pennsylvania |
2017-04-10 | PHASE2 |
| NCT03768479 | UNKNOWN | Estrogen Receptor-positive Breast Cancer; Fulvestrant |
First Affiliated Hospital Xi'an Jiaotong University |
2017-03-05 | |
| NCT02530411 | UNKNOWN | Neoplasms |
Velindre NHS Trust |
2015-04 | PHASE2 |
| NCT03241810 | TERMINATED | Metastatic Breast Cancer |
Elevation Oncology |
2017-08-15 | PHASE2 |
| NCT02389842 | COMPLETED | Advanced Solid Tumours; Breast Cancer |
Royal Marsden NHS Foundation Trust |
2015-03-25 | PHASE1 |
| NCT00100854 | COMPLETED | Lung Cancer |
Translational Oncology Research International |
2004-10-28 | PHASE2 |
| NCT02630693 | COMPLETED | Breast Cancer |
Canadian Cancer Trials Group |
2016-04-08 | PHASE2 |
| NCT03377101 | WITHDRAWN | Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2018-08-07 | PHASE2 |
| NCT02983604 | TERMINATED | Advanced Estrogen Receptor Positive HER2- Breast Cancer |
Gilead Sciences |
2017-01-10 | PHASE1; PHASE2 |
| NCT03324061 | COMPLETED | Pharmacokinetics |
Eagle Pharmaceuticals, Inc. |
2017-11-30 | PHASE1 |
| NCT03507088 | COMPLETED | Metastatic Breast Cancer |
Zhimin Shao |
2015-09-01 | |
| NCT02049957 | COMPLETED | Breast Cancer |
Calithera Biosciences, Inc |
2014-02-13 | PHASE2 |
| NCT02437318 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2015-07-23 | PHASE3 |
| NCT01989780 | COMPLETED | Metastatic Breast Cancer |
Japan Breast Cancer Research Group |
2014-01 | PHASE2 |
| NCT01266213 | UNKNOWN | Metastatic Breast Cancer; Estrogen Receptor Positive Tumor; Breast Cancer Nos Premenopausal |
Samsung Medical Center |
2010-12 | PHASE2 |
| NCT01556191 | COMPLETED | Stage IV Lung Cancer |
Intergroupe Francophone de Cancerologie Thoracique |
2012-05-15 | PHASE2 |
| NCT02088684 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2014-05-19 | PHASE1 |
| NCT02384746 | TERMINATED | Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2015-06-02 | PHASE1 |
| NCT02599714 | COMPLETED | Advanced and Metastatic Breast Cancer |
AstraZeneca |
2015-12-07 | PHASE1 |
| NCT03430466 | TERMINATED | Breast Cancer |
Kyoto Breast Cancer Research Network |
2017-06-22 | PHASE2 |
| NCT02404051 | UNKNOWN | Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Locally Advanced Malignant Neoplasm |
Consorzio Oncotech |
2015-12 | PHASE3 |
| NCT02422615 | COMPLETED | Advanced Breast Cancer |
Novartis Pharmaceuticals |
2015-06-09 | PHASE3 |
| NCT02392611 | COMPLETED | Solid Tumors and Lymphomas |
Gilead Sciences |
2015-03-16 | PHASE1 |
| NCT02383030 | UNKNOWN | Metastatic Breast Cancer |
Consorzio Oncotech |
2015-11 | PHASE3 |
| NCT02137083 | COMPLETED | Metastatic Breast Cancer |
Fudan University |
2014-04 | PHASE2 |
| NCT01797120 | COMPLETED | Metastatic Breast Cancer |
PrECOG, LLC. |
2013-05-31 | PHASE2 |
| NCT02795039 | COMPLETED | Healthy |
Fresenius Kabi |
2016-06 | PHASE1 |
| NCT02107703 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-07-22 | PHASE3 |
| NCT02549430 | COMPLETED | Breast Cancer |
Fondazione Sandro Pitigliani |
2012-10 | PHASE2 |
| NCT01339442 | COMPLETED | Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
Washington University School of Medicine |
2011-11-14 | PHASE1 |
| NCT02640755 | COMPLETED | Solid Malignancies |
AstraZeneca |
2016-01-28 | PHASE1 |
| NCT02374099 | TERMINATED | Breast Neoplasms |
Celgene |
2015-03-13 | PHASE2 |
| NCT01441947 | COMPLETED | Breast Cancer |
Massachusetts General Hospital |
2011-10 | PHASE2 |
| NCT02394496 | UNKNOWN | Metastatic Breast Cancer |
Consorzio Oncotech |
2007-11 | PHASE3 |
| NCT02116803 | COMPLETED | Solid Tumors |
Novartis Pharmaceuticals |
2014-05-28 | PHASE2; PHASE3 |
| NCT01597388 | COMPLETED | Advanced Metastatic Breast Cancer |
AstraZeneca |
2012-05-08 | PHASE1 |
| NCT02260661 | COMPLETED | Advanced Solid Malignancies; Breast Cancer - ER+, HER2 -; Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation |
AstraZeneca |
2014-11 | PHASE1 |
| NCT00543127 | TERMINATED | Breast Cancer |
Spanish Breast Cancer Research Group |
2007-11 | PHASE3 |
| NCT01560416 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2012-06 | PHASE2 |
| NCT01633060 | TERMINATED | Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2012-10-03 | PHASE3 |
| NCT02447328 | COMPLETED | Locally Advanced or; Metastatic Breast Cancer |
AstraZeneca |
2015-05-29 | PHASE4 |
| NCT01602380 | COMPLETED | Hormone Receptor Positive Breast Cancer |
AstraZeneca |
2012-10-17 | PHASE3 |
| NCT01437566 | COMPLETED | Breast Cancer |
Genentech, Inc. |
2011-10 | PHASE2 |
| NCT02000193 | UNKNOWN | Breast Cancer |
Sun Yat-sen University |
2013-11 | PHASE2 |
| NCT02219789 | COMPLETED | Estrogen Receptor Positive; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
Mayo Clinic |
2014-12-05 | PHASE1 |
| NCT01597193 | COMPLETED | Breast Cancer |
Pfizer |
2012-04-30 | PHASE1 |
| NCT02140437 | WITHDRAWN | Carcinoma Breast Stage IV |
Fudan University |
2014-03 | PHASE2 |
| NCT02115594 | WITHDRAWN | Breast Cancer |
Syndax Pharmaceuticals |
2014-04 | PHASE2 |
| NCT02072512 | UNKNOWN | Metastatic Breast Cancer |
Hospital Affiliated to Military Medical Science, Beijing |
2014-01 | PHASE2 |
| NCT02026973 | COMPLETED | Normal Healthy Volunteers |
Mayo Clinic |
2014-03 | PHASE1 |
| NCT02345772 | TERMINATED | HER2-positive Breast Cancer; ER-positive Breast Cancer |
Western Regional Medical Center |
2014-07 | PHASE1; PHASE2 |
| NCT02000596 | TERMINATED | Metastatic Breast Cancer |
University of Maryland, Baltimore |
2014-01 | PHASE2 |
| NCT01142401 | COMPLETED | Metastatic Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2010-05-26 | PHASE2 |
| NCT00629616 | COMPLETED | Breast Cancer |
UNICANCER |
2007-10 | PHASE2 |
| NCT01610284 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2012-08-07 | PHASE3 |
| NCT01528345 | TERMINATED | Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2012-04 | PHASE2 |
| NCT00921115 | COMPLETED | Invasive Breast Cancer |
University of Kansas Medical Center |
2009-05 | PHASE2 |
| NCT01219699 | COMPLETED | Advanced Solid Tumors With an Alteration of the PIK3CA Gene; Estrogen Receptor Positive Breast Cancer |
Novartis Pharmaceuticals |
2010-10-05 | PHASE1 |
| NCT01714128 | WITHDRAWN | Breast Cancer |
Washington University School of Medicine |
2013-06 | |
| NCT01942135 | COMPLETED | Metastatic Breast Cancer |
Pfizer |
2013-09-26 | PHASE3 |
| NCT00816582 | TERMINATED | Breast Cancer |
British Columbia Cancer Agency |
2010-11-30 | |
| NCT01202591 | COMPLETED | FGFR Inhibition, Pharmacokinetics, Biomarkers; ER+ Breast Cancer |
AstraZeneca |
2010-12 | PHASE1; PHASE2 |
| NCT00390455 | COMPLETED | Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2006-09-15 | PHASE3 |
| NCT01394016 | COMPLETED | Advanced Cancer |
Eli Lilly and Company |
2009-12-07 | PHASE1 |
| NCT01300351 | COMPLETED | Breast Cancer |
AstraZeneca |
2011-03 | PHASE3 |
| NCT00545077 | COMPLETED | Breast Cancer |
Spanish Breast Cancer Research Group |
2007-11-06 | PHASE3 |
| NCT00871858 | COMPLETED | Breast Cancer |
Institut Bergonié |
2008-03-18 | PHASE2 |
| NCT00752986 | TERMINATED | Breast Cancer |
Genzyme, a Sanofi Company |
2008-12 | PHASE2 |
| NCT01377324 | COMPLETED | Metastatic Breast Cancer |
University Medical Center Groningen |
2011-05 | PHASE2 |
| NCT01186796 | COMPLETED | Healthy |
Mayo Clinic |
2009-06 | PHASE1 |
| NCT00903006 | TERMINATED | Breast Cancer |
M.D. Anderson Cancer Center |
2009-11 | PHASE1; PHASE2 |
| NCT00688194 | UNKNOWN | Breast Cancer |
Gruppo Italiano Mammella (GIM) |
2008-05 | PHASE3 |
| NCT00570921 | COMPLETED | Breast Cancer |
Mara Chambers |
2008-04 | PHASE2 |
| NCT00932152 | TERMINATED | Non-small Cell Lung Cancer; Postmenopausal Women |
University of Pittsburgh |
2010-09 | PHASE2 |
| NCT00075764 | COMPLETED | Breast Cancer |
SWOG Cancer Research Network |
2004-04 | PHASE3 |
| NCT01160718 | COMPLETED | Breast Cancer |
Swiss Cancer Institute |
2010-08 | PHASE2 |
| NCT01231659 | COMPLETED | Postmenopausal Women; Locally Advanced Metastatic Breast Cancer; Metastatic Breast Cancer |
Novartis Pharmaceuticals |
2011-08-09 | PHASE2 |
| NCT00811369 | COMPLETED | Metastatic Breast Cancer |
Ontario Clinical Oncology Group (OCOG) |
2009-08 | PHASE2 |
| NCT00372996 | TERMINATED | Breast Neoplasms |
Pfizer |
2007-02 | PHASE2 |
| NCT00057941 | COMPLETED | Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2003-09 | PHASE2 |
| NCT00201864 | COMPLETED | Breast Cancer |
Ohio State University Comprehensive Cancer Center |
2005-09 | PHASE2 |
| NCT00927511 | UNKNOWN | Breast Cancer |
Regina Elena Cancer Institute |
2008-10 | PHASE2 |
| NCT00728949 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2008-08 | PHASE2 |
| NCT00754325 | COMPLETED | Advanced Breast Cancer |
Bristol-Myers Squibb |
2008-09 | PHASE2 |
| NCT00534417 | COMPLETED | Metastatic Breast Cancer |
Accelerated Community Oncology Research Network |
2007-10 | PHASE2 |
| NCT01344031 | COMPLETED | Estrogen Receptor Positive; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2011-04-21 | PHASE1 |
| NCT00944918 | COMPLETED | Progression-free Survival |
AstraZeneca |
2008-12 | PHASE3 |
| NCT00334295 | COMPLETED | Endometrial Carcinoma |
AstraZeneca |
2002-12 | PHASE2 |
| NCT00451555 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2007-04-11 | PHASE2 |
| NCT00570258 | TERMINATED | Metastatic Breast Cancer |
University of Arkansas |
2006-09 | PHASE2 |
| NCT00774878 | TERMINATED | Breast Neoplasms |
Sanofi |
2008-10 | PHASE2 |
| NCT01004419 | WITHDRAWN | Carcinoma, Non Small Cell Lung |
University of Wisconsin, Madison |
2009-11 | PHASE1 |
| NCT00722072 | TERMINATED | Breast Cancer |
OHSU Knight Cancer Institute |
2008-07 | PHASE2 |
| NCT00405938 | COMPLETED | Breast Cancer; Breast Neoplasms |
SCRI Development Innovations, LLC |
2006-11 | PHASE2 |
| NCT00626106 | COMPLETED | Breast Cancer; Breast Tumors; Metastatic Cancer |
NantCell, Inc. |
2008-03-27 | PHASE2 |
| NCT00217464 | TERMINATED | Prostate Cancer |
Roswell Park Cancer Institute |
2004-06 | PHASE2 |
| NCT00278915 | COMPLETED | Puberty, Precocious; McCune-Albright Syndrome |
AstraZeneca |
2006-01-31 | PHASE2 |
| NCT00476645 | COMPLETED | Prostatic Neoplasms; Prostate Cancer |
Stanford University |
2006-09 | PHASE2 |
| NCT00256698 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-01 | PHASE3 |
| NCT00099437 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2005-02-13 | PHASE3 |
| NCT00423917 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2007-08 | PHASE2 |
| NCT00454805 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
2007-03 | PHASE2 |
| NCT00259090 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-04 | PHASE2 |
| NCT00357110 | COMPLETED | Breast Cancer |
AstraZeneca |
2006-04 | PHASE2 |
| NCT00082810 | COMPLETED | Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2004-03 | PHASE2 |
| NCT00313170 | COMPLETED | Advanced Breast Cancer; Metastatic Breast Cancer |
AstraZeneca |
2006-05-30 | PHASE2 |
| NCT00183963 | TERMINATED | Breast Carcinoma |
University of Southern California |
2006-08 | PHASE2 |
| NCT00617188 | COMPLETED | Ovarian Cancer |
Masonic Cancer Center, University of Minnesota |
2007-06 | PHASE2 |
| NCT00006903 | UNKNOWN | Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7 |
Gynecologic Oncology Group |
2004-08-30 | PHASE2 |
| NCT00305448 | COMPLETED | Advanced Breast Cancer; Metastatic Breast Cancer |
AstraZeneca |
2006-03 | PHASE2 |
| NCT00274469 | COMPLETED | Metastatic Breast Cancer |
AstraZeneca |
2006-02-06 | PHASE2 |
| NCT00146601 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2004-06 | PHASE2 |
| NCT00241449 | COMPLETED | Breast Cancer; Metastasis |
AstraZeneca |
1998-11 | PHASE3 |
| NCT00244998 | COMPLETED | Prostate Cancer |
Roswell Park Cancer Institute |
2005-09 | PHASE2 |
| NCT00328120 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
2004-04 | PHASE1 |
| NCT00012025 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2001-05 | PHASE2 |
| NCT00010153 | TERMINATED | Breast Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2000-11 | PHASE3 |
| NCT00234403 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-05 | PHASE2 |
| NCT00272740 | COMPLETED | Breast Neoplasms |
AstraZeneca |
2000-03 | PHASE2 |
| NCT00126464 | UNKNOWN | Breast Cancer |
Cedars-Sinai Medical Center |
2004-11 | |
| NCT00327769 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
2005-11 | PHASE3 |
| NCT00635713 | COMPLETED | Advanced Breast Cancer |
AstraZeneca |
1997-05 | PHASE3 |
| NCT00093002 | COMPLETED | Breast Cancer |
AstraZeneca |
2004-06 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
Fulvestrant (ICI-182780)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Fulvestrant (ICI-182780) Mechanism of Action: ER Inhibition in Breast Cancer Cell Research
- Fulvestrant (ICI-182780): Selectivity & Specificity
- Fulvestrant (ICI-182780) Working Concentration | Cell Culture | Treatment
- Fulvestrant (ICI-182780) Solubility in DMSO
- Fulvestrant (ICI-182780) Stock Solution
- Fulvestrant (ICI-182780) Storage
- Fulvestrant (ICI-182780) Stability
- Fulvestrant (ICI-182780) Combination Database
- Fulvestrant (ICI-182780) Molecular Weight
- Fulvestrant (ICI-182780) SMILES
- Fulvestrant (ICI-182780) CAS Number
- Fulvestrant (ICI-182780) Chemical Structure (2D and 3D)
- Fulvestrant (ICI-182780) IC50 for Cell-based and Cell-free Assays
- Fulvestrant (ICI-182780) Sigma (I4409)? Try a better option.
- Fulvestrant (ICI-182780) MedChemExpress (HY-13636)? Try a better option.
- Fulvestrant (ICI-182780) APExBIO (A1428)? Try a better option.
- Fulvestrant (ICI-182780) Tocris (1047)? Try a better option.
- Fulvestrant (ICI-182780) Cayman (10011269)? Try a better option.
- Fulvestrant (ICI-182780) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.